Skip to main content

Advertisement

Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

Table 1 Patient characteristics

From: Tumor-infiltrating immune cell profiles and their change after neoadjuvant chemotherapy predict response and prognosis of breast cancer

Characteristic   Number = 121 %
Menopausal status Premenopausal 60 49.6
Postmenopausal 61 50.4
Clinical staging IIA 19 15.7
IIB 34 28.1
IIIA 40 33.1
IIIB 8 6.6
IIIC 20 16.5
Clinical staging primary tumor cT1-2 52 43.0
cT3-4 69 57.0
Clinical staging nodes cN0 39 32.2
cN1 36 29.8
cN2-3 46 38.0
Tumor type Ductal invasive 113 93.4
Lobular invasive 5 4.1
Other 3 2.5
Tumor grade GI 7 5.8
GII 39 32.2
GIII 61 50.4
Unknown 14 11.5
Hormone-sensitivity Negative 39 32.2
Positive 80 66.1
No data 2 1.7
HER2 overexpression Negative 87 71.9
Positive 29 24.0
Unknown 5 4.1
Triple negative No 90 74.4
Yes 26 21.5
Unknown 5 4.1
IHC subtype ER+ and/or PR+ and HER2- 61 50.4
ER+ and/or PR+ and HER2+ 16 13.2
ER- and PR- and HER2+ 13 10.7
ER- and PR- and HER2- 26 21.5
Non classifiable 5 4.1
Chemotherapy regimen AC x 4 – Docetaxel x 4 97 80.2
Sequential anthracyclines-paclitaxel 10 8.3
Non anthracycline 2 1.7
Non anthracycline-taxane 4 3.3
Concomitant anthracyclines–taxane 8 6.6
Trastuzumab treatment No 99 81.8
Neoadjuvant 17 14.0
Adjuvant 5 4.1
Local treatment Mastectomy 67 55.3
Breast conservation surgery (BCT) 53 43.8
  1. ER, estrogen receptor, HER2, human epidermal growth factor receptor 2, IHC, immunohistochemistry; PR, progesterone receptor.